1. Opening Hook
Akums entered Q2 FY26 with a war chest bigger than some small-cap market caps, and exited with EBITDA margins that quietly slipped off a cliff. While API prices played villain, fixed costs joined the party uninvited. Management rolled out Africa, Europe, and 2027 as comfort blankets, hoping investors would ignore the present. Zambia sounds exciting, Europe sounds premium, but Q2 numbers sounded… painful. Still, volumes grew, cash flowed, and optimism remained stubbornly intact. This concall was less about celebrating results and more about explaining why patience is still the most valuable dosage.
Read on — because the future is glossy, even if the present needs a margin resuscitation.
2. At a Glance
- Revenue down 1.5% YoY – Growth took a coffee break.
- EBITDA down 22% YoY – Operating leverage went missing.
- EBITDA margin at 9.3% – From pharma to paracetamol-level relief.
- PAT down to ₹43 crore – Profits felt the API fever.
- Net cash ₹1,649 crore – Balance sheet flex still intact.
- H1 free cash flow ₹1,044 crore – Cash rich, earnings poor.
3. Management’s Key Commentary
“Revenue remained flat while margins saw a dip due to API price declines.”
(Blame APIs, not execution… mostly.) 😏
“API prices for top 200 molecules declined ~8% YoY.”
(Cost-plus model just learned subtraction.)
“CDMO volumes grew over 7% despite flat IPM growth.”
(Selling more, earning less — impressive, in a way.)
“New facilities ramp-up slower than expected.”
(Capex hangover officially acknowledged.)
“Domestic branded formulations margins at 21.6%.”
(One business behaving like it should.)
“Zambia JV to commence production in CY 2028.”
(Future Akums is
